In Suit, Aria Says Sequenom 'Misrepresents' Scope of Patent for Noninvasive Prenatal Testing | GenomeWeb

By Monica Heger

In a lawsuit
filed this week, Aria Diagnostics alleges that Sequenom is overly aggressive in its enforcement of a broad patent related to the use of circulating cell-free DNA in maternal plasma to diagnose fetal aneuploidies.

In its complaint, filed with the US District Court for the Northern District of California, Aria requests a declaratory judgment that a test it is developing to diagnose fetal aneuploidies does not infringe Sequenom's patent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.